JFB et GP2A 2013
Conferences > Archives > JFB2013

Orateurs confirmés


Orateurs Confirmés

L11 - Computer assisted drug design of protein therapeutics
Dr Nicolas BAURINDr Nicolas BAURIN
(SANOFI-AVENTIS, Vitry sur Seine, France)

Read more
L05 - Développement d’un nucléotide antisens actif par voie orale pour le traitement des MICI
Dr Salvatore BELLINVIADr Salvatore BELLINVIA
(GIULIANI SPA, Milano, Italy)
L01 - From PPARg agonists to Selective PPARg Modulator (SPPARM): a long story!
Dr Catherine DACQUETDr Catherine DACQUET
(INSTITUT DE RECHERCHES SERVIER, Suresnes, France)

Read more
L04 - Nouvelles perspectives thérapeutiques dans les maladies inflammatoires intestinales
Prof. Pierre DESREUMAUXProf. Pierre DESREUMAUX
(UNIVERSITÉ LILLE 2, Lille, France)

Read more
L06 - Design and synthesis of aminosteroids and steroidal neuromuscular blocking agents
Prof. Xianming HUProf. Xianming HU
(WUHAN UNIVERSITY, Wuhan, Hubei, China)

Read more
L07 - L’oligomérisation des récepteurs couplés aux protéines G et complexes protéiques associés: de nouvelles opportunités pour le drug design
Dr Ralf JOCKERSDr Ralf JOCKERS
(UNIVERSITÉ PARIS DESCARTES, Paris, France)

Read more
L09 - The dynamics of protein-DNA recognition in the telomere
Dr Charles LAUGHTONDr Charles LAUGHTON
(UNIVERSITY PARK NOTTINGHAM, Nottingham, United Kingdom)

Read more
L08 - Structure, function and inhibition of human protein kinase CK2
Prof. Marc LE BORGNEProf. Marc LE BORGNE
(UNIVERSITÉ CLAUDE BERNARD LYON 1, Lyon, France)

Read more
L02 - Serendipity: facteur de diversité
Prof. Benoit RIGOProf. Benoit RIGO
(HEI, Lille, France)

Read more
L03 - Myéloperoxydase: cible thérapeutique dans les syndromes inflammatoires chroniques
Mr Pierre VAN ANTWERPENMr Pierre VAN ANTWERPEN
(ULB, Bruxelles, Belgium)

Read more
L10 - Dual regulation of estrogen receptor with novel selective estrogen receptor modulators (SERMs)
Prof. Haibing ZHOUProf. Haibing ZHOU
(WUHAN UNIVERSITY, Wuhan, China)

Read more

Communications orales

OC03 - PEA reduces colon and systemic inflammation in mice models of crohn’s disease
Ms Mireille AL HOUAYEK
(UCL, Bruxelles, Belgium)
OC05 - Novel development in coumarins as FXIIa inhibitors: Improvement of solubility
Mrs Charlotte BOUCKAERT
(UNAMUR, Namur, Belgium)
OC04 - Nouvelle voie de synthèse de derivés furo[3,2-b]pyridiniques à activité mélatoninergique
Ms Audrey COUHERT
(ICOA, Orléans, France)
OC10 - Design and synthesis of 2-indolyl-thieno[2.3-d]pyrimidinones as potential inhibitors of VEGFR2
Dr Stéphanie HESSE
(UNIVERSITÉ DE LORRAINE, Metz, France)
OC14 - An unusual borontribromide-mediated, one-pot bromination/cyclisation reaction. application to the synthesis of a highly strained cyclopenta[1,3]cycopropa[1,2-b]pyrrolizin-8-one
Mr Jean-Pierre JOURDAN
(CERMN, Caen, France)
OC02 - Dynamique du complexe CD1d-ligand: Hypothèse mécanistique sur le profil d’activation des iNKT
Mr Xavier LAURENT
(INSTITUT DE CHIMIE PHARMACEUTIQUE ALBERT LESPAGNOL , Lille, France)
OC01 - Acyl-benzothiazol-2-one: a privileged scaffold in the design of PPAR modulators
Dr Nicolas LEBEGUE
(UNIVERSITÉ LILLE 2, Lille, France)
OC08 - Discovery of highly potent, selective and safe reversers of BCRP-mediated multidrug resistance
Ms Florine LECERF-SCHMIDT
(UJF, Grenoble, France)
OC06 - Synthesis and evaluation of harmine derivatives as new cytostatic compounds on cancerous cells
Mrs Celine MEINGUET
(UNAMUR, Namur, Belgium)
OC11 - 1,4-dihydropyridines as antiproliferative and multidrug resistance reversal agents
Mr Conor O'SHEA
(TRINITY COLLEGE DUBLIN, Dublin, Ireland)
OC13 - Asymmetric synthesis of Rhodotorulic acid analogues with potential antibacterial activities
Ms Marine PILLON
(UNIVERSITÉ DE PICARDIE JULES VERNE, Amiens, France)
OC07 - Antiplasmodial SARs in 2-trichloromethylazaheterocyclic series
Dr Nicolas PRIMAS
(FACULTÉ DE PHARMACIE DE MARSEILLE, Marseille, France)
OC09 - Metalloprotease inhibitors targeting: new strategy for chondrosarcoma treatment
Dr Magali VIVIER
(UMR 990 INSERM, Clermont-Ferrand, France)

Sponsors

Exposants

Copyright 2018 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys